IL16 and COVID-19: In the longitudinal analysis of patients’ disease development, we found that the levels of five cytokines and chemokines, IL-10, IP-10, SCGF-β, IL-16, and IL-18, significantly changed during the progression from mild to severe and from severe to mild COVID-19.